Stock Ratings / Health Care / ATRA / financials

TNYA (46) OKYO (52) TVGN (40) NMRA (42) ⌘ Pro Terminal →

Atara Biotherapeutics Inc. (ATRA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.01 -6.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.91

Atara Biotherapeutics Inc. (ATRA) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $85.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATRA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Atara Biotherapeutics Inc. (NASDAQ: ATRA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $8.01 (-6.10% 1D, market cap $85.6M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ATRA ranks #249 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATRA compare to TNYA and OKYO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATRA carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 85.0%. By comparison, TNYA (Tenaya Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $90.8M) and OKYO (OKYO Pharma Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $78.7M). Among the 5-stock peer group, ATRA leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATRA?

▼

Per ATRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001604464), Atara Biotherapeutics Inc. generated $120.8M in revenue (-6.3% YoY), $32.7M in net income, and -$50.9M in free cash flow against $20.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.91 (-1.29%)🧬 Disciplined Float (-0.12% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-1.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATRA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY ATRA SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+16/20 pts (30% of score)

FRED Regime × Technicals: 27% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (-0.12% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$9.48-3.2% Next Q

Q2 (-2Q)

Grade C$9.18-6.4% Next Q

Q3 (-1Q)

Grade C$8.59-6.8% Next Q

Current

Grade D+$8.01-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATRA currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.20) and Max Pain ($8.41) forces dealer call-delta covering toward $20.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.12% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ATRA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $8.6M

FY24

Rev $128.9M

FY25

Rev $120.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$120.8M	52%	29.7%	$32.7M	-$50.9M	95%
FY 2024	$128.9M	52%	-64.7%	-$85.4M	-$69.0M	-45%
FY 2023	$8.6M	52%	-80%	-$276.1M	-$193.0M	85%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATRA)

✓Walkthrough of ATRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +67.92%🛡️ HOLDING TREND SUPPORT

2026-10-30O $8.53H $8.53L $7.72C $8.01VOL 30.0K

RES: $10.82SUP: $7.90SMA50: $9.20SMA200: $7.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATRA Butterfly Map → + Track ATRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATRA)

Health Care Rank #249 of 1016 ⚔️ TNYA vs ATRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATRA vs. TNYA, OKYO, TVGN, NMRA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Atara Biotherapeutics Inc. (ATRA) ranks #249 by composite RQD confidence (54/100, grade D+) and #681 by equity capitalization ($85.6M). Within this direct 5-issuer industry benchmark cohort, ATRA leads on earnings valuation at N/A trailing P/E, while ATRA leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ATRA currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATRA ACTIVE Atara Biotherapeutics Inc.	D+	54/100	—	—	85.0%	-6.10%	$85.6M	Benchmark Subject
TNYA Tenaya Therapeutics Inc.	D	46/100	—	—	-35.0%	-7.78%	$90.8M	/tnya-vs-atra →
OKYO OKYO Pharma Limited	D+	52/100	—	—	—	-2.00%	$78.7M	/okyo-vs-atra →
TVGN Tevogen Inc.	D-	40/100	—	—	-35.0%	-2.48%	$95.2M	/tvgn-vs-atra →
NMRA Neumora Therapeutics Inc.	D-	42/100	—	—	-35.0%	-5.43%	$73.0M	/nmra-vs-atra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001604464

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atara Biotherapeutics Inc. (ATRA) reported GAAP revenue of $120.8M (-6.3% vs. FY2024 revenue of $128.9M , and +1308.7% cumulative change since FY2023) , GAAP net income of $32.7M, operating cash flow of -$50.9M, and free cash flow of -$50.9M (+26.1% YoY). On the balance sheet, ATRA closed FY2025 with $20.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$120.8M	$32.7M	-$50.9M	-$50.9M	$20.2M	—
FY2024 (FY)	2024-12-31	$128.9M	-$85.4M	-$68.7M	-$69.0M	$109.1M	—
FY2023 (FY)	2023-12-31	$8.6M	-$276.1M	-$193.0M	-$193.0M	—	—

3. ATRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ATRA compare to TNYA and OKYO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ATRA?

Where is ATRA trading relative to its 50-day, 200-day, and 52-week technical levels?

ATRA last traded at $8.01 (-6.10% on volume of 29,968 shares), positioning the stock -12.93% below its 50-day simple moving average ($9.20) and +4.30% above its 200-day simple moving average ($7.68). Across its 52-week range of $3.92 to $19.15, ATRA sits at the 26.9% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.01 to $9.01).

ATRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Atara Biotherapeutics Inc. (ATRA)?

In FY 2025 (10-K), ATRA converted $120.8M of revenue into a 52% gross margin, 29.7% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ATRA RQD Cockpit ATRA 12M Forecast ATRA Earnings & Move ATRA Dividends & DRIP ATRA Insiders & 13F ATRA Whale Options ATRA Profit Sankey ATRA News & Why